9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by J. Goldman & Co LP

J. Goldman & Co LP purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,414 shares of the company’s stock, valued at approximately $1,154,000.

Several other institutional investors also recently bought and sold shares of the business. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares in the last quarter. Greenline Wealth Management LLC purchased a new position in shares of Protagonist Therapeutics during the 4th quarter valued at approximately $27,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $30,000. Allworth Financial LP acquired a new stake in Protagonist Therapeutics in the 2nd quarter valued at $31,000. Finally, Quantbot Technologies LP acquired a new stake in Protagonist Therapeutics in the 2nd quarter valued at $42,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Price Performance

PTGX opened at $151.50 on Thursday. The firm has a market capitalization of $9.80 billion, a price-to-earnings ratio of 147.09 and a beta of 1.78. The company’s 50 day simple moving average is $137.15 and its two-hundred day simple moving average is $111.81. Protagonist Therapeutics, Inc. has a 1-year low of $54.50 and a 1-year high of $160.81.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The business had revenue of $213.47 million during the quarter, compared to analyst estimates of $212.03 million. The firm’s revenue for the quarter was up 3746.8% compared to the same quarter last year. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 4.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $149.11, for a total value of $9,805,622.71. Following the completion of the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at $78,055,804.58. This trade represents a 11.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,000 shares of company stock worth $17,818,139 in the last three months. 5.19% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PTGX shares. Weiss Ratings raised shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $110.00 to $186.00 in a report on Monday, August 10th. Wall Street Zen upgraded shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 22nd. UBS Group raised shares of Protagonist Therapeutics to a “buy” rating in a research note on Monday, August 10th. Finally, Citigroup upped their price target on shares of Protagonist Therapeutics from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.53.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.